Alok Tayi is the Vice President of Life Sciences at Egnyte where he is responsible for building and executing the company's strategy for the life sciences market segment. Rahul Chaturvedi is the Founder and CEO of Clora, the leading marketplace where people go to discover, build, and manage on-demand life science teams.
Read MoreAs Executive Vice President and General Manager of Ancestry.com, a 1.6 billion dollar technology company, Ken led the launch of AncestryDNA, a large-scale e-commerce genetic genealogy test with revenues of > $500M. In 2019, Ken led the launch AncestryHealth, an e-commerce LDT genetic health product on a next-generation sequencing (NGS) platform.
Read MoreIbraheem Mahmood has an extensive life science and finance background that spans more than 20 years. His experience includes previous roles in Lifescience M&A and Fundraising at Nomura, Lifescience Equity Research at Investec and Business Development and Corporate Venture Capital at Shire Pharmaceuticals.
Read MoreDr. Raymond J. Tesi has been President, Chief Executive Officer and acting Chief Medical Officer since the formation of INmune Bio in September 2015.
Read MoreDr. Matthew Bio is President & CEO at Snapdragon Chemistry. Matthew began his career in chemistry more than 20 years ago developing continuous processes for the manufacture and purification of acrylates at the former Rohm & Haas company. Matthew then moved to Columbia University and earned a PhD in Chemistry.
Read MoreAlexander Titus is the Founder of Bioeconomy.XYZ and the Chief Strategy Officer (CSO) at the Advanced Regenerative Manufacturing Institute (ARMI), where his career focuses on the intersection of technology and public benefit, with experience spanning the private and public sectors, as well as non-profits and academia.
Read MoreJames (Jim) Burns, Ph.D., joined Locanabio in December 2019 as CEO and Board member. Kathie M. Bishop, Ph.D., joined Locanabio in August 2019 as CSO. Dr. Bishop has 20 years’ experience in leading translational research and drug development, with a focus on novel therapeutics in neurological and rare diseases.
Read MoreSeth Lederman is a physician, scientist and founder and executive officer of innovative biopharmaceuticals companies. Prior to founding Tonix, among the companies Dr. Lederman founded was Targent Pharmaceuticals, which developed late-stage oncology drugs, including pure-isomer levofolinic acid (levoleucovorin).
Read MoreVictor Hanson-Smith is the Head of Computational Biology at Verge Genomics and is one of the world's leaders in mathematical modeling of eukaryotic genome evolution and function. He has co-authored 13 publications in peer-reviewed journals such as Nature and Science, and his work has been featured in the NYTimes and The Washington Post.
Read MoreDr. Maria Soloveychik is the co-founder and CEO of SyntheX, a therapeutics company focused on accelerating drug discovery using synthetic biology. The company’s core technologies, ToRPPIDO and ToRNeDO, rely on genetic engineering and evolutionary selection to synthesize and identify compounds that disrupt protein-protein interactions or lead to selective target degradation.
Read MoreBob has been President of Imagion Biosystems since February 2015 and has led the company through the recent restructuring and recapitalization efforts. Previous employment experience includes Pres/GM for Silicon Biosystems and a career in marketing and sales management with more than 25 years experience.
Read MoreNick Damiano is a serial entrepreneur with broad experience in medical devices and digital health. He has 15 years of experience as a healthcare entrepreneur, engineer, and leader. He is currently Co-Founder & CEO of Zenflow, which is developing a novel office-based therapy to relieve symptoms of benign prostatic hyperplasia (BPH), which affects over 500 million men globally.
Read More
